...
首页> 外文期刊>Genes, Chromosomes and Cancer >Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.
【24h】

Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.

机译:在药物选择的细胞系和难治性ALL患者中激活药物耐药基因MDR1 / P-糖蛋白的随机染色体重排的细胞遗传学和分子表征。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Drug resistance, both primary and acquired, is a major obstacle to advances in cancer chemotherapy. In vitro, multidrug resistance can be mediated by P-glycoprotein (PGY1), a cell surface phosphoglycoprotein that acts to efflux natural products from cells. PGY1 is encoded by the MDR1 gene located at 7q21.1. Overexpression of MDR1 has been demonstrated in many cancers, both in patient tumors and in cell lines selected with a variety of chemotherapeutic agents. Recent studies in drug-selected cell lines and patients samples have identified hybrid mRNAs comprised of an active, but apparently random, gene fused 5' to MDR1. This observation indicates that random chromosomal rearrangements, such as translocations and inversions, leading to "capture" of MDR1 by constitutively expressed genes may be a mechanism for activation of this gene following drug exposure. In this study, fluorescence in situ hybridization (FISH) using whole chromosome paints (WCP) and bacterial artificial chromosome (BAC)-derived probes showed structural rearrangements involving 7q in metaphase and interphase cells, and comparative genomic hybridization (CGH) revealed high levels of amplification at chromosomal breakpoints. In an adriamycin-selected resistant colon cancer line (S48-3s/Adr), WCP4/WCP7 revealed t(4;7)(q31;q21) and BAC-derived probes demonstrated that the breakpoint lay between MDR1 and sequences 500-1000 KB telomeric to it. Similarly, in a subline isolated following exposure to actinomycin D (S48-3s/ActD), a hybrid MDR1 gene composed of heme oxygenase-2 sequences (at 16p13) fused to MDR1 was identified and a rearrangement confirmed with WCP7 and a subtelomeric 16p probe. Likewise, in a paclitaxel-selected MCF-7 subline where CASP sequences (at 7q22) were shown to be fused to MDR1, WCP7 showed an elongated chromosome 7 with a homogeneously staining regions (hsr); BAC-derived probes demonstrated that the hsr was composed of highly amplified MDR1 and CASP sequences. In all three selected cell lines, CGH demonstrated amplification at breakpoints involving MDR1 (at 7q21) and genes fused to MDR1 at 4q31, 7q22, and 16p13.3. Finally, in samples obtained from two patients with drug refractory ALL, BAC-derived probes applied to archived marrow cells demonstrated that a breakpoint occurred between MDR1 and sequences 500-1000 KB telomeric to MDR1, consistent with a random chromosomal rearrangement. These results support the proposal that random chromosomal rearrangement leading to capture and activation of MDR1 is a mechanism of acquired drug resistance.
机译:无论是原发性还是获得性耐药,都是癌症化疗进展的主要障碍。在体外,多药耐药性可通过P-糖蛋白(PGY1)介导,P-糖蛋白是一种细胞表面磷酸糖蛋白,可从细胞中排出天然产物。 PGY1由位于7q21.1的MDR1基因编码。 MDR1的过表达已在许多癌症中证实,无论是在患者肿瘤中还是在用多种化学治疗剂选择的细胞系中。最近在药物选择的细胞系和患者样品中进行的研究已鉴定出杂合的mRNA,这些杂合的mRNA由与MDR1 5'融合的活性基因(显然是随机的)组成。该观察表明,随机染色体重排,例如易位和倒位,导致组成性表达的基因“捕获” MDR1,可能是药物暴露后激活该基因的机制。在这项研究中,使用全染色体涂料(WCP)和细菌人工染色体(BAC)衍生的探针进行的荧光原位杂交(FISH)显示了中期和间期细胞中涉及7q的结构重排,而比较基因组杂交(CGH)显示了高水平的在染色体断裂点扩增。在阿霉素选择的抗性结肠癌株系(S48-3s / Adr)中,WCP4 / WCP7揭示了t(4; 7)(q31; q21),而BAC衍生的探针证明该断点位于MDR1和序列500-1000 KB之间端粒。同样,在暴露于放线菌素D(S48-3s / ActD)后分离的亚系中,鉴定了由与MDR1融合的血红素加氧酶2序列(16p13)组成的杂合MDR1基因,并用WCP7和亚端粒16p探针确认了重排。同样,在紫杉醇选择的MCF-7子系中,CASP序列(在7q22处)显示与MDR1融合,WCP7显示出带有均一染色区(hsr)的细长染色体7。 BAC衍生的探针表明hsr由高度扩增的MDR1和CASP序列组成。在所有三个选定的细胞系中,CGH在涉及MDR1(在7q21)和在4q31、7q22和16p13.3与MDR1融合的基因的断点处显示扩增。最后,在从两名患有药物难治性ALL的患者中获得的样品中,应用于存档的骨髓细胞的BAC衍生探针证明了MDR1与MDR1端粒的500-1000 KB端粒之间出现了断点,这与随机染色体重排一致。这些结果支持这样的建议,即导致MDR1捕获和激活的随机染色体重排是获得性耐药的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号